Publication Type:

Journal Article

Source:

Asian Journal of Pharmaceutical and Clinical Research, Asian Journal of Pharmaceutical and Clinical Research, Volume 8, Number 5, p.71-72 (2015)

URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84940934713&partnerID=40&md5=02120ef26f9c651f248b4541ec11c98a

Keywords:

abdominal cramp, article, autoimmune disease, autoimmune hemolytic anemia, blister, chill, clinical article, coughing, cyanosis, cytokine release syndrome, disease severity, dizziness, drug response, drug safety, drug tolerance, drug withdrawal, dyspnea, erythema, fatigue, fever, headache, hemophilia, hot flush, human, hyperglycemia, hyperhidrosis, hypoglycemia, hypotension, India, myalgia, nausea and vomiting, pain, Patient monitoring, primary immune thrombocytopenia, pruritus, rash, Rhinitis, rigor, rituximab, seizure, shivering, skin abrasion, tachycardia, thorax pain, throat disease, thrombocytopenia, thrombotic thrombocytopenic purpura, ulcer, urinary tract infection

Abstract:

Rituximab therapy has become a promising therapeutic option for various non-malignant hematological disorders, after being reported by many case reports. The objective of this study was to evaluate the immediate, infusion-related adverse drug events (ADE) of patients who received rituximab for non-malignant, hematological disorders, in a tertiary healthcare center in India. 14 patients (6 with primary immune thrombocytopenia, 4 with autoimmune hemolytic anemia, 3 with thrombotic thrombocytopenic purpura, 1 with acquired hemophilia) were enrolled in the study. Patients were assessable for immediate infusion-related toxicity noted predominately within 5 hrs of administration of rituximab infusion. Rituximab therapy was tolerated without major ADE. None of the patients experienced high-grade adverse events. The population who experienced ADE (Grades 1-2) frequently had toxicities that suspected to result from infusion-related cytokine release syndrome (IRCRS) and sometimes required cessation of the infusion and supportive intervention. Patients were monitored for 20 types of ADEs associated with IRCRS. 11 types of; mild to moderate (Grades 1 and 2) toxicities resulting from IRCRS were experienced by patients. Mean patients who experienced IRCRS was 1.95 (13.93%), whereas majority of the study population tolerated therapy without IRCRS (86.78%). Among other toxicities, Grade 2 urinary tract infection (UTI) (n=2, 14.29%); Grade 2 hyperglycemia (n=1, 7.14%) and Grade 1 myalgia (n=1, 7.14%) were observed. Toxicity profile of patients with non-malignant hematological disorders shows that rituximab is a safer biological therapy. © 2015, Asian Journal of Pharmaceutical and Clinical Research. All Rights Reserved.

Notes:

cited By 0

Cite this Research Publication

Aa Neetha, N.K.a Panicker, and Sidharthan, Nb, “Immediate adverse drug events with rituximab therapy in non-malignant hematological disorders”, Asian Journal of Pharmaceutical and Clinical Research, vol. 8, pp. 71-72, 2015.